TARGET AUDIENCE

Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care Professionals, Industry Professionals, Regulatory and Government Officials, Patient Advocates, and Nursing Professionals.

STATEMENT OF NEED/PROGRAM OVERVIEW

The Society for Neuro-Oncology’s Annual Meeting is the largest and most influential meeting for multidisciplinary collaboration in the field of Neuro-Oncology in North America. The latest advances in Central Nervous System (CNS) cancers are shared with an international audience that includes a variety of sub-specialties involved in basic and translational research, clinical as well as symptom management research. The meeting fosters opportunities to explore collaborations that will positively influence outcomes for patients with CNS cancers. This year’s meeting will highlight the theme Crossing the Translational Divide: From Neurons to Novel Therapies. This activity is a collaboration of researchers and clinicians disseminating new knowledge to healthcare professionals in order to provide the highest quality of patient care to improve patient outcomes. The goal is to provide healthcare professionals with updated viewpoints, strategies, collaboration opportunities and an increased knowledge base to maximize treatment and improve outcomes for brain tumor patients.

EDUCATIONAL OBJECTIVES

After participating in this CME activity, participants should be able to:

• Summarize recent basic science discoveries in neuro-oncology and discuss their implications for emerging therapeutic strategies.
• Identify key drivers of health inequities and disparities in neuro-oncology and apply evidence-based strategies to improve equitable access to diagnosis, treatment, and outcomes for patients with central nervous system (CNS) malignancies.
• Evaluate recent advances in multidisciplinary approaches to the diagnosis and treatment of adult patients with central nervous system (CNS) malignancies.
• Evaluate recent advances in the multidisciplinary management of pediatric, adolescent, and young adult patients with CNS malignancies and their implications for patient care.
• Evaluate current challenges and emerging strategies in clinical trial design and treatment development for patients with CNS malignancies and cancer predisposition syndromes.

_{Physician Accreditation StatemenT}

The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

_{Instructions to Receive Credit, Claim Certificate of Participation}

In order to receive credit or claim your certificate of participation for this activity, the participant must attend the meeting in-person and complete the program evaluation. A CME/CE evaluation link will be emailed to each participant within the coming weeks after the conference conclusion from the Society for Neuro-Oncology with the subject line "Claim CME, or Certificate of Participation for the 2026 SNO Annual Meeting." Physicians should only claim CME credit commensurate with the time they spent in the activity.

For technical assistance with claiming CME credit, please email academy@soc-neuro-onc.org

Deadline to claim CE Credit is Friday January 8, 2027, at 11:59 pm ET.

_{Refund/Cancellation Policy}

The deadline for cancellations with refund is Friday, October 30, 2026. Cancellations must be received in writing, and a $50 cancellation fee will be assessed. Cancellations received after the deadline date cannot be refunded, but the meeting registration can be transferred to another person with written authorization.

Please note that your SNO membership must be current if you have chosen to register as a SNO member. SNO reserves the right to confirm that you have registered in the correct category. Payment must be received in full before access to the meeting can be granted. Email all cancellation and transfer requests to Program Registrar Caroline Noor, caroline@soc-neuro-onc.org.

_{Disclosure of Relevant Financial Relationships}

The Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months . All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology in accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO.

_{Disclosure of Unlabeled Use}

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

_Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

_{SNO CME Contact Information}

For more information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Buchanan, RN at melesa@soc-neuro-onc.org